Johnson & Johnson (NYSE:JNJ) Shares Acquired by Revisor Wealth Management LLC

Revisor Wealth Management LLC lifted its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 108.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,377 shares of the company's stock after buying an additional 2,798 shares during the quarter. Revisor Wealth Management LLC's holdings in Johnson & Johnson were worth $892,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. WealthTrak Capital Management LLC purchased a new position in Johnson & Johnson during the fourth quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. purchased a new position in Johnson & Johnson during the fourth quarter worth approximately $29,000. Conquis Financial LLC purchased a new position in Johnson & Johnson during the fourth quarter worth approximately $33,000. Bernard Wealth Management Corp. purchased a new position in Johnson & Johnson during the fourth quarter worth approximately $36,000. Finally, Runnymede Capital Advisors Inc. purchased a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $38,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Up 0.2%

JNJ stock traded up $0.34 during midday trading on Friday, hitting $155.90. 3,482,521 shares of the company's stock were exchanged, compared to its average volume of 8,059,757. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The business has a 50-day simple moving average of $153.68 and a two-hundred day simple moving average of $154.09. The stock has a market capitalization of $375.11 billion, a PE ratio of 17.34, a P/E/G ratio of 2.36 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The business had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were paid a $1.30 dividend. The ex-dividend date was Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.34%. Johnson & Johnson's payout ratio is presently 57.84%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on JNJ shares. Raymond James Financial decreased their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Barclays decreased their target price on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Wall Street Zen upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their target price for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Finally, Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Eleven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.